Skip Navigation



Brain Advance Access published online on November 5, 2009
Brain, doi:10.1093/brain/awp276
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dalakas, M. C.
Right arrow Articles by Dambrosia, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dalakas, M. C.
Right arrow Articles by Dambrosia, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author(s) 2009. Published by Oxford University Press on behalf of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reply to: Comment on alemtuzumab and inclusion body myositis

Marinos C. Dalakas1, Goran Rakocevic1, Jens Schmidt1, Beverly McElroy1, Michael O. Harris-Love2, Joseph A. Shrader2, Ellen W. Levy2 and James Dambrosia3

1 Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke 2 Rehabilitation Medicine Department, Clinical Centre, National Institutes of Health (NIH) 3 Biostatistics Branch National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA

Correspondence to: Prof. Marinos Dalakas, Imperial College, Division of Neurosciences, Burlington Danes Building, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK E-mail: m.dalakos@imperial.ac.uk

The first 10% of the full text of this article appears below.

Sir, Dr Greenberg misinterprets several important aspects of our study, including the scope and applied methodology. Below we have addressed the points raised in his correspondence.

This was a proof-of principle molecular clinicopathological study designed to investigate the effect of alemtuzumab on endomysial T cells and disease progression; it was not primarily a trial of clinical efficacy. As stated, alemtuzumab did not significantly improve patients’ strength and function but only induced short-term stability based on the difference between two time periods. Contrary to Dr Greenberg's comments, outcome was not based on any predetermined percentages that were subsequently amended. The percentages mentioned by Dr Greenberg were used only to power the sample size. As our results show, these percentages do not relate . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?